<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VES</journal-id>
<journal-id journal-id-type="hwp">spves</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Endovascular Surg</journal-id>
<journal-title>Vascular and Endovascular Surgery</journal-title>
<issn pub-type="ppub">1538-5744</issn>
<issn pub-type="epub">1938-9116</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1538574413493678</article-id>
<article-id pub-id-type="publisher-id">10.1177_1538574413493678</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Research Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Patency in Arteriovenous Grafts in Hemodialysis Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mousa</surname>
<given-names>Albeir Y.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
<xref ref-type="corresp" rid="corresp1-1538574413493678"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patterson</surname>
<given-names>William</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="aff2-1538574413493678">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abu-Halimah</surname>
<given-names>Shadi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hass</surname>
<given-names>Stephen M.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhalbouni</surname>
<given-names>Saadi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadek</surname>
<given-names>Betro T.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1538574413493678">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nanjundappa</surname>
<given-names>Aravinda</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Modak</surname>
<given-names>Asmita</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff2-1538574413493678">2</xref>
<xref ref-type="aff" rid="aff3-1538574413493678">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stone</surname>
<given-names>Patrick A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emmett</surname>
<given-names>Mary</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-1538574413493678">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AbuRahma</surname>
<given-names>Ali F.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1538574413493678">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1538574413493678">
<label>1</label>Department of Surgery, Robert C. Byrd Health Sciences Center, West Virginia University, Charleston, WV, USA</aff>
<aff id="aff2-1538574413493678">
<label>2</label>CAMC Health Education and Research Institute, Charleston, WV, USA</aff>
<aff id="aff3-1538574413493678">
<label>3</label>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA</aff>
<author-notes>
<corresp id="corresp1-1538574413493678">Albeir Y. Mousa, Department of Surgery, Robert C. Byrd Health Sciences Center, West Virginia University, 3110 MacCorkle Ave., SE, Charleston, WV 25304, USA. Email: <email>amousa@hsc.wvu.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>6</issue>
<fpage>438</fpage>
<lpage>443</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Objective:</title>
<p>It is difficult to maintain a working access for patients on hemodialysis. Despite current Dialysis Outcome Quality Initiatives recommendations of “Fistula First,” not everyone qualifies for a fistula, and those patients undergoing the alternative treatment, a graft, can experience graft failure. This study examines factors associated with arteriovenous graft (AVG) patency.</p>
</sec>
<sec>
<title>Methods:</title>
<p>A retrospective analysis was completed for all the patients who had an AVG during 2005 to 2010. Data were collected from electronic medical records, including date of first and subsequent interventions, salvage technique (surgical vs percutaneous), medical comorbidities, and use of antiplatelet medications (aspirin and clopidogrel). Continuous variables were compared with 2 sample <italic>t </italic>tests, and categorical variables with chi-square/Fisher exact test. Logistic regression was used to determine the odds ratio for risk factors associated with patency. A <italic>P</italic> value of &lt;.05 was considered significant. All analyses were done using SAS 9.2 (SAS Institute Inc, Cary, North Carolina).</p>
</sec>
<sec>
<title>Results:</title>
<p>A total of 193 unique patients had an AVG. Of the 193 patients, 64% were female, 83% were hypertensive, and 64% were diabetic. The locations of the grafts were 80% arm, 15% forearm, and 5% thigh. Configurations, including loop and straight, were 34% and 63%, respectively. Comorbidities were not associated with patency. Primary patency was not found to be different with respect to location and configuration of graft and type of intervention. Primary patency for patients taking only aspirin (n = 43) and only clopidogrel (n = 17) were significantly different from patients on a combination of aspirin and clopidogrel (n = 7), with a <italic>P</italic> = .0051 and <italic>P</italic> = .0447, respectively.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>Neither location nor configuration affects the primary patency of AVGs. Aspirin alone is not inferior to aspirin and clopidogrel. Further prospective studies may be warranted to establish a consensus regarding medications and patency with AVGs.</p>
</sec>
</abstract>
<kwd-group>
<kwd>hemodialysis</kwd>
<kwd>renal</kwd>
<kwd>failure</kwd>
<kwd>clopidogrel</kwd>
<kwd>aspirin</kwd>
<kwd>percutaneous</kwd>
<kwd>patency</kwd>
<kwd>surgical</kwd>
<kwd>looped</kwd>
<kwd>straight</kwd>
<kwd>primary</kwd>
<kwd>secondary</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1538574413493678">
<title>Introduction</title>
<p>Due to its comparatively low complication rate and high patency rate, autologous arteriovenous (AV) fistula remains the gold standard of access for hemodialysis. According to Dialysis Outcome Quality Initiatives (DOQI),<sup>
<xref ref-type="bibr" rid="bibr1-1538574413493678">1</xref><xref ref-type="bibr" rid="bibr2-1538574413493678"/>–<xref ref-type="bibr" rid="bibr3-1538574413493678">3</xref>
</sup> the most preferred hemodialysis access is the native veins,<sup>
<xref ref-type="bibr" rid="bibr4-1538574413493678">4</xref>
</sup> but when all veins are exhausted, grafts must be used. It is estimated that more than 5 00 000 access procedures are done annually for hemodialysis patients in the United States<sup>
<xref ref-type="bibr" rid="bibr5-1538574413493678">5</xref>,<xref ref-type="bibr" rid="bibr6-1538574413493678">6</xref>
</sup>; however, maintaining the patency of these hemodialysis access grafts remains problematic and requires special attention.</p>
<p>Creation of a functional AV fistula may be difficult in patients with hypoplastic superficial arm veins and in patients with exhausted superficial veins after multiple autogenous access procedures. Also, arteriovenous graft (AVG) implantations can be considered in morbidly obese patients with superficial veins lying deep beyond their fatty tissue.<sup>
<xref ref-type="bibr" rid="bibr7-1538574413493678">7</xref>
</sup> When the hemodialysis patient is not a candidate for the creation of an AV fistula, implantation of a standard AVG is needed to enable or maintain hemodialysis treatment.<sup>
<xref ref-type="bibr" rid="bibr6-1538574413493678">6</xref>,<xref ref-type="bibr" rid="bibr8-1538574413493678">8</xref>
</sup>
</p>
<p>Maintaining the patency of hemodialysis, access grafts remain a challenge to the vascular specialist, and it is best to recognize a failing graft prior to thrombosis. This can be achieved by noting an elevation in the venous pressure, an increase in recirculation time, arm swelling, excessive bleeding, reduced access flow rate, or prominent pulsation with reduced thrill on physical examination. Factors associated with failure are important and need to be recognized and considered prior to the placement of an AVG. Until now, there has not been a consensus regarding the effect of medications or type of configuration on graft patency. Our aim is to determine the factors associated with AVG patency.</p>
</sec>
<sec id="section2-1538574413493678" sec-type="methods">
<title>Methods and Definitions</title>
<sec id="section3-1538574413493678">
<title>Design</title>
<p>A retrospective study including all patients who had an AVG inserted during the past 5 years (2005-2010) was undertaken to analyze factors associated with graft patency. The patients were selected using the code for an arteriovenous access (39.27). Since this code applies regardless of the type of access, fistula, or graft, the patient’s file was scrubbed to include only graft patients using the following additional codes: 39.42 (revision of the graft), 39.49 (declot/thrombectomy), 39.50 (angioplasty), and 39.90 (stent). The final sample of eligible patients was determined using this methodology.</p>
</sec>
<sec id="section4-1538574413493678">
<title>Sample</title>
<p>The patients included in the study had an AVG inserted during the period 2005 to 2010. A total of 193 patients met the criteria using the methods described earlier. All the patients were followed regardless of their patency status. We wanted to determine the factors associated with patency in those patients determined to be ineligible for an AV fistula.</p>
</sec>
<sec id="section5-1538574413493678">
<title>Definitions</title>
<p>The recommended standards for reports dealing with arteriovenous hemodialysis accesses are as follows.<sup>
<xref ref-type="bibr" rid="bibr9-1538574413493678">9</xref>
</sup>
</p>
<list list-type="simple">
<list-item>
<p>
<italic>Primary patency</italic> (intervention-free access survival) was defined as the interval from time of access placement to any intervention designed to maintain or reestablish patency, to access thrombosis, or the time of measurement of patency.</p>
</list-item>
<list-item>
<p>
<italic>Assisted primary patency</italic> (thrombosis-free access survival) was defined as the interval from time of access placement to access thrombosis or time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a patent access.</p>
</list-item>
<list-item>
<p>
<italic>Secondary patency</italic> (access survival until abandonment) was defined as the interval from time of access placement to access abandonment or time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to reestablish the functionality of thrombosed access.</p>
</list-item>
</list>
</sec>
<sec id="section6-1538574413493678">
<title>Data Collection</title>
<p>Data were collected from electronic medical records for 193 patients. The data collected consisted of age, gender, medical comorbidities, date of graft insertion, date of all interventions, antiplatelet medications used (aspirin and clopideral), and location and configuration of graft.</p>
</sec>
<sec id="section7-1538574413493678">
<title>Statistical Analysis</title>
<p>All descriptive statistics were done. All continuous variables were compared with 2 sample <italic>t </italic>tests, and categorical variables were compared with chi-square/Fisher exact test whenever appropriate. Kaplan-Meier survival analysis was used to calculate patency rates. A <italic>P</italic> value of &lt;.05 was considered significant. All analyses were done using SAS 9.2 (SAS Institute, Inc, Cary, North Carolina).</p>
<sec id="section8-1538574413493678">
<title>Ethical Approval </title>
<p>This study was approved by the Charleston Area Medical Center Institutional Review Board.</p>
</sec>
</sec>
</sec>
<sec id="section9-1538574413493678">
<title>Results</title>
<sec id="section10-1538574413493678">
<title>Patient Characteristics</title>
<p>A total of 193 AVGs in 193 patients met the inclusion criteria for the study. The average age was 62.49 ± 14.99 years (range: 15-94 years), and 36% were male and 64% were female. In all, 160 (83%) patients were hypertensive, 47% had coronary artery disease, and 64% were diabetic.</p>
<p>Of the grafts inserted 122 (63%) were straight, while the rest (37%) had a loop configuration. A majority of the grafts were placed in the arm (80%) and forearm (15%), whereas very few (5%) were inserted in the thigh. Most interventions for straight grafts were percutaneous (67%), while loop grafts were surgical (50%), which is statistically different with a <italic>P</italic> value of .014, respectively (<xref ref-type="table" rid="table1-1538574413493678">Table 1</xref>).</p>
<table-wrap id="table1-1538574413493678" position="float">
<label>Table 1.</label>
<caption>
<p>Graft Location and Intervention by Configuration.</p>
</caption>
<graphic alternate-form-of="table1-1538574413493678" xlink:href="10.1177_1538574413493678-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Loop (N = 72), N (%)</th>
<th>Straight (N = 124), N (%)</th>
<th>
<italic>P </italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Location of graft</td>
</tr>
<tr>
<td> Arm</td>
<td>42 (59.15)</td>
<td>112 (91.80)</td>
<td>&lt;.0001<sup>a</sup>
</td>
</tr>
<tr>
<td> Forearm</td>
<td>28 (39.44)</td>
<td>1 (0.82)</td>
<td>&lt;.0001<sup>a</sup>
</td>
</tr>
<tr>
<td> Thigh</td>
<td>1 (1.41)</td>
<td>9 (7.38)</td>
<td>.0952</td>
</tr>
<tr>
<td colspan="4">Primary intervention </td>
</tr>
<tr>
<td> Percutaneous</td>
<td>35 (49.30)</td>
<td>82 (67.21)</td>
<td>.0140<sup>a</sup>
</td>
</tr>
<tr>
<td> Surgical</td>
<td>36 (50.70)</td>
<td>40 (32.79)</td>
<td>.0140<sup>a</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1538574413493678">
<p>
<sup>a </sup>Statistically significant at .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-1538574413493678">
<title>Risk Factors for Loss of Patency</title>
<p>Patients were compared for their primary patency with respect to age, gender, and comorbidities, and these were not found to be significantly different. Although not statistically significant, patients with coronary artery disease who were on antiplatelet therapy had a longer patency (5.4 months) than patients with other comorbid conditions (<xref ref-type="table" rid="table2-1538574413493678">Table 2</xref>).</p>
<table-wrap id="table2-1538574413493678" position="float">
<label>Table 2.</label>
<caption>
<p>Risk Factors and Patency.<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-1538574413493678" xlink:href="10.1177_1538574413493678-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>n</th>
<th>Primary Patency (Months)</th>
<th>
<italic>P </italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Age </td>
</tr>
<tr>
<td> &lt;60</td>
<td>73</td>
<td>3.75 ± 5.29 (0-36)</td>
<td rowspan="3">.3442</td>
</tr>
<tr>
<td> 60-74</td>
<td>79</td>
<td>5.37 ± 7.70 (0-37)</td>
</tr>
<tr>
<td> <underline>&gt;</underline>75</td>
<td>41</td>
<td>4.51 ± 7.29 (0-33)</td>
</tr>
<tr>
<td colspan="4">Sex</td>
</tr>
<tr>
<td> Male</td>
<td>70</td>
<td>4.00 ± 4.73 (0-26)</td>
<td rowspan="2">.3159</td>
</tr>
<tr>
<td> Female</td>
<td>123</td>
<td>4.90 ± 7.72 (0-37)</td>
</tr>
<tr>
<td colspan="4">Comorbidities</td>
</tr>
<tr>
<td> Hypertension</td>
<td>160</td>
<td>4.61 ± 6.78 (0-37)</td>
<td>.8669</td>
</tr>
<tr>
<td> Coronary artery disease</td>
<td>90</td>
<td>5.42 ± 7.54 (0-36)</td>
<td>.1112</td>
</tr>
<tr>
<td> Diabetes mellitus</td>
<td>124</td>
<td>5.01 ± 7.06 (0-37)</td>
<td>.2278</td>
</tr>
<tr>
<td> Smoking</td>
<td>36</td>
<td>3.22 ± 4.06 (0-17)</td>
<td>.0651</td>
</tr>
<tr>
<td> Hyperlipidemia</td>
<td>81</td>
<td>4.79 ± 7.53 (0-36)</td>
<td>.7096</td>
</tr>
<tr>
<td> Systemic lupus  erythematosis </td>
<td>4</td>
<td>3.25 ± 2.63 (1-7)</td>
<td>.6946</td>
</tr>
<tr>
<td> Peripheral arterial disease </td>
<td>29</td>
<td>4.93 ± 8.22 (0-33)</td>
<td>.7605</td>
</tr>
<tr>
<td colspan="4">Location</td>
</tr>
<tr>
<td> Arm</td>
<td>154</td>
<td>4.48 ± 6.44 (0-37)</td>
<td rowspan="2">.5027</td>
</tr>
<tr>
<td> Forearm</td>
<td>29</td>
<td>5.68 ± 9.19 (0-33)</td>
</tr>
<tr>
<td colspan="4">Configuration</td>
</tr>
<tr>
<td> Loop</td>
<td>71</td>
<td>5.80 ± 8.33 (0-37)</td>
<td rowspan="2">.0837</td>
</tr>
<tr>
<td> Straight</td>
<td>122</td>
<td>3.86 ± 5.633 (0-36)</td>
</tr>
<tr>
<td colspan="4">Primary intervention</td>
</tr>
<tr>
<td> Percutaneous</td>
<td>117</td>
<td>5.24 ± 6.86 (0-36)</td>
<td rowspan="2">.0880</td>
</tr>
<tr>
<td> Surgical</td>
<td>76</td>
<td>3.53 ± 6.59 (0-37)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1538574413493678">
<p>
<sup>a</sup> Statistically significant at .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>For graft salvage, percutaneous techniques were performed in 61% of the patients, while 39% had an open surgical intervention at primary patency. Primary patency was not found to be different with respect to location and configuration of the graft and the type of intervention (<xref ref-type="table" rid="table3-1538574413493678">Table 3</xref>).</p>
<table-wrap id="table3-1538574413493678" position="float">
<label>Table 3.</label>
<caption>
<p>Medications and Patency.</p>
</caption>
<graphic alternate-form-of="table3-1538574413493678" xlink:href="10.1177_1538574413493678-table3.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>n</th>
<th>Primary Patency (Months)</th>
<th>
<italic>P </italic>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin alone </td>
<td>43</td>
<td>5.72 ± 8.72 (0-37)</td>
<td rowspan="2">.7976</td>
</tr>
<tr>
<td>Clopidogrel alone </td>
<td>17</td>
<td>5.11 ± 6.49 (0-26)</td>
</tr>
<tr>
<td>Aspirin alone</td>
<td>43</td>
<td>5.72 ± 8.72 (0-37)</td>
<td rowspan="2">.0051<sup>a</sup>
</td>
</tr>
<tr>
<td>Only on aspirin + clopidogrel</td>
<td>7</td>
<td>1.57 ± 1.27 (0-3)</td>
</tr>
<tr>
<td>Clopidogrel alone </td>
<td>17</td>
<td>5.11 ± 6.49 (0-26)</td>
<td rowspan="2">.0447<sup>a</sup>
</td>
</tr>
<tr>
<td>Only on aspirin + clopidogrel</td>
<td>7</td>
<td>1.57 ± 1.27 (0-3)</td>
</tr>
<tr>
<td>Aspirin alone</td>
<td>43</td>
<td>5.72 ± 8.72 (0-37)</td>
<td rowspan="2">.1761</td>
</tr>
<tr>
<td>No medications </td>
<td>71</td>
<td>3.73 ± 4.89 (0-31)</td>
</tr>
<tr>
<td>Clopidogrel alone </td>
<td>17</td>
<td>5.11 ± 6.49 (0-26)</td>
<td rowspan="2">.3293</td>
</tr>
<tr>
<td>No medications </td>
<td>71</td>
<td>3.73 ± 4.89 (0-31)</td>
</tr>
<tr>
<td>Only on aspirin + clopidogrel</td>
<td>7</td>
<td>1.57 ± 1.27 (0-3)</td>
<td rowspan="2">.0074<sup>a</sup>
</td>
</tr>
<tr>
<td>No medications </td>
<td>71</td>
<td>3.73 ± 4.89 (0-31)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1538574413493678">
<p>
<sup>a </sup>Statistically significant at .05.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We compared primary patency with use of antiplatelet medications (<xref ref-type="table" rid="table3-1538574413493678">Table 3</xref>). Patients were categorized into 4 different groups: patients taking only aspirin (n = 43), only clopidogrel (n = 17), a combination of aspirin and clopidogrel (n = 7), and patients on no medications (n = 71). The primary patency for patients on aspirin (n = 43) and or clopidogrel (n = 17) was significantly improved than for patients on a combination of aspirin and clopidogrel (n = 7) with a <italic>P</italic> value of .0051 and .0447, respectively (<xref ref-type="table" rid="table3-1538574413493678">Table 3</xref>).</p>
</sec>
<sec id="section12-1538574413493678">
<title>Patency</title>
<p>The average primary, primary assisted, and secondary patency was 4.6, 17.1, and 18.5 months, respectively. Overall, the follow-up time from access placement to loss of follow-up, secondary failure, or study end was 154 months or 12.8 patient-years (ie, 0.06 year per patient). The 5-, 10-, and 15-month patency rates are depicted in <xref ref-type="table" rid="table4-1538574413493678">Table 4</xref> and <xref ref-type="fig" rid="fig1-1538574413493678">Figure 1</xref>. Primary assisted and secondary patency rates were found to be statistically similar.</p>
<fig id="fig1-1538574413493678" position="float">
<label>Figure 1.</label>
<caption>
<p>Primary and secondary patency from access placement.</p>
</caption>
<graphic xlink:href="10.1177_1538574413493678-fig1.tif"/>
</fig>
<table-wrap id="table4-1538574413493678" position="float">
<label>Table 4.</label>
<caption>
<p>Patency Rates of AVG Insertions at 5, 10, and 15 Months and Number of Patients at Risk at 5, 10, and 15 Months at the End of the Interval (n).</p>
</caption>
<graphic alternate-form-of="table4-1538574413493678" xlink:href="10.1177_1538574413493678-table4.tif"/>
<table>
<thead>
<tr>
<th>Patency</th>
<th>5 Months, n (%)</th>
<th>10 Months, n (%)</th>
<th>15 Months, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary patency</td>
<td>50 (25.9)</td>
<td>23 (11.9)</td>
<td>10 (5.2)</td>
</tr>
<tr>
<td>Primary-assisted patency</td>
<td>114 (59.1)</td>
<td>93 (48.2)</td>
<td>78 (40.4)</td>
</tr>
<tr>
<td>Secondary patency </td>
<td>120 (62.2)</td>
<td>98 (50.8)</td>
<td>82 (42.5)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1538574413493678">
<p>Abbreviation: AVG, arteriovenous graft.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-1538574413493678">
<title>Arteriovenous Graft Function</title>
<p>Of the 193 grafts placed, the outcomes were indeterminate in 18 grafts due to death (n = 13) and renal transplantation (n = 5). The remaining 175 grafts were followed. We found that 106 grafts failed, and 69 remained patent and were successfully used for dialysis. On average, 3.6 interventions per patient (range: 1-26) were performed on the 106 grafts that required a salvage procedure to keep them functioning. At primary patency loss, 51 required only thrombectomy, 49 required only angioplasty, and 64 required both. Ultimately, the 106 grafts were removed or abandoned due to various reasons, such as infection (n = 25), malfunction (n = 32), complete occlusion (n = 18), multiple times thrombosis (n = 21), steal (n = 7), venous hypertension (n = 1), and ischemic ulcer (n = 1).</p>
</sec>
</sec>
<sec id="section14-1538574413493678">
<title>Discussion</title>
<p>According to the current DOQI guidelines, a fistula should be the first procedure attempted in every hemodialysis patient.<sup>
<xref ref-type="bibr" rid="bibr10-1538574413493678">10</xref><xref ref-type="bibr" rid="bibr11-1538574413493678"/><xref ref-type="bibr" rid="bibr12-1538574413493678"/>–<xref ref-type="bibr" rid="bibr13-1538574413493678">13</xref>
</sup> However, placement of an AVG is inevitable in certain patients. Most studies have shown that three-fourth of these AVGs will fail within 1 year.<sup>
<xref ref-type="bibr" rid="bibr14-1538574413493678">14</xref><xref ref-type="bibr" rid="bibr15-1538574413493678"/>–<xref ref-type="bibr" rid="bibr16-1538574413493678">16</xref>
</sup> Therefore, a comprehensive evaluation of graft patency and an assessment of failure are imperative to minimize the substantial burden of all salvage procedures to maintain working access and to minimize the financial burden involved with graft failure. A recent cost benefit analysis estimated that more than 1 billion dollars are spent annually on vascular access procedures.<sup>
<xref ref-type="bibr" rid="bibr8-1538574413493678">8</xref>,<xref ref-type="bibr" rid="bibr17-1538574413493678">17</xref>
</sup>
</p>
<p>Trimarchi et al<sup>
<xref ref-type="bibr" rid="bibr18-1538574413493678">18</xref>
</sup> demonstrated a better patency rate and a lower thrombosis rate for AVGs with the use of clopidogrel (Plavix), with no increase in bleeding complications. Our study demonstrated that aspirin and or clopidogrel are not inferior to a combination of aspirin and clopidogrel. This finding may contradict other data regarding the effect of clopidogrel on femoral distal bypass grafts in patients with peripheral vascular disease.<sup>
<xref ref-type="bibr" rid="bibr19-1538574413493678">19</xref>,<xref ref-type="bibr" rid="bibr20-1538574413493678">20</xref>
</sup> However, this difference in results may be due to the nature of the 2 diseases and the hemodynamic characteristic for each graft. The cost-effective utilization of these medications should be reconsidered, especially since the high cost of clopidogrel makes it unobtainable for some patients.<sup>
<xref ref-type="bibr" rid="bibr21-1538574413493678">21</xref>
</sup>
</p>
<p>A recent randomized, double-blind, placebo study<sup>
<xref ref-type="bibr" rid="bibr14-1538574413493678">14</xref>
</sup> conducted in 13 centers (including our institution) in the United States to evaluate the effect of Dipyridamole plus aspirin on hemodialysis graft patency has demonstrated a primary patency rate of 23% (95% confidence interval [CI],<sup>
<xref ref-type="bibr" rid="bibr22-1538574413493678">22</xref>
</sup> 18-28) at 1 year for patients on Dipyridamole plus aspirin versus 28% (95% CI, 23-34) in the placebo group. This study concluded that treatment with Dipyridamole plus aspirin can prolong the duration of primary-unassisted patency (hazard ratio, 0.82; 95% CI, 0.68-0.98; <italic>P</italic> = .03). Another randomized, double-blind study by Kaufman et al<sup>
<xref ref-type="bibr" rid="bibr15-1538574413493678">15</xref>
</sup> evaluated the effect of clopidogrel plus aspirin on the prevention of hemodialysis access graft thrombosis, and it failed to show any benefit on patency for patients on clopidogrel plus aspirin versus placebo (hazard ratio, 0.81; 95% CI, 0.49-1.40). However, bleeding complications were increased, and the study was terminated after enrolling 200 participants on the advice of the Data Safety Monitoring Board. We concluded that double antiplatelet therapy (clopidogrel plus aspirin) was of little benefit in regard to patency; however, we did not encounter any significant bleeding in these patients. A recent study by Stone et al demonstrated the safety of clopidogrel in the perioperative period. A similar study to evaluate the effect of low-dose Coumadin on AVG patency did not validate any benefit on graft thrombosis, but bleeding hazards were increased.<sup>
<xref ref-type="bibr" rid="bibr23-1538574413493678">23</xref>
</sup> In a double-blind randomized analysis, 24 patients were randomized to receive 4000 mg fish oil versus placebo. Fish oil was associated with better patency, less thrombosis, and improved venous outflow resistance. This study proposed that the biologic nature of fish oil may remodel the thombogenicity of AVGs and minimize their failure.<sup>
<xref ref-type="bibr" rid="bibr24-1538574413493678">24</xref>
</sup> These results have been reproduced by others.<sup>
<xref ref-type="bibr" rid="bibr25-1538574413493678">25</xref><xref ref-type="bibr" rid="bibr26-1538574413493678"/><xref ref-type="bibr" rid="bibr27-1538574413493678"/>–<xref ref-type="bibr" rid="bibr28-1538574413493678">28</xref>
</sup>
</p>
<p>A retrospective study using multivariate analysis and logistic regression concluded that an age &gt;65, smoking, and diabetes predicted graft failure.<sup>
<xref ref-type="bibr" rid="bibr29-1538574413493678">29</xref>,<xref ref-type="bibr" rid="bibr30-1538574413493678">30</xref>
</sup> However, our study reinforced that age was not a predictive risk of graft failure similar to what others have demonstrated.<sup>
<xref ref-type="bibr" rid="bibr29-1538574413493678">29</xref>
</sup> The astonishing finding of a better primary patency for patients with coronary artery disease may be contributed to prolonged antiplatelet therapy before access intervention; however, this can be a type 1 error, secondary to the retrospective nature of our study. The patients with loop or straight grafts were not associated with a significantly higher primary patency, although this has been echoed in other studies.<sup>
<xref ref-type="bibr" rid="bibr31-1538574413493678">31</xref>,<xref ref-type="bibr" rid="bibr32-1538574413493678">32</xref>
</sup>
</p>
<p>The most common cause of graft failure is venous outflow stenosis or obstruction; therefore, the ideal salvage procedure has to consider central venous outflow evaluation. Declotting procedures are usually done using percutaneous techniques or open surgical repair.<sup>
<xref ref-type="bibr" rid="bibr33-1538574413493678">33</xref><xref ref-type="bibr" rid="bibr34-1538574413493678"/><xref ref-type="bibr" rid="bibr35-1538574413493678"/><xref ref-type="bibr" rid="bibr36-1538574413493678"/><xref ref-type="bibr" rid="bibr37-1538574413493678"/>–<xref ref-type="bibr" rid="bibr38-1538574413493678">38</xref>
</sup> Several studies have compared the results between surgical thrombectomy and percutaneous graft declotting. In this study, the mean primary patency for procedures with percutaneous interventions was not significantly higher than surgical interventions.</p>
<p>The percutaneous declotting technique has evolved since the early 1980s,<sup>
<xref ref-type="bibr" rid="bibr39-1538574413493678">39</xref>
</sup> with more advances in therapy from low-dose thrombolytic infusions through a single catheter to a mechanical thrombectomy using an angiojet principle, to angioplasty with a high-pressure balloon, such as Conquest Bard Peripheral Balloon, or combinations of the last 2 options. Adequate angioplasty results can be determined by measuring the intragraft pressure, and if the midgraft pressure is less than 40% of the systemic pressure, we consider angioplasty adequate. A sluggish flow, a high midgraft pressure, or obvious anatomic abnormalities can be determined at the time of the angioplasty and can be evaluated and treated as needed. Ultimately, the management of the platelet plug at the arterial anastomosis and at the venous stenosis is an adjunct procedure to the declotting, and we perform this with angioplasty using a 6-mm balloon at the arterial anastomosis and an 8- to 10-mm balloon at the venous stenosis area.</p>
<p>To the best of our knowledge, this is the first report in the literature to evaluate the outcomes of dual antiplatelet therapy versus aspirin and clopideral alone, evaluate patency, and to review the factors associated with percutaneous salvage interventions for AVG failure. However, this study does have some limitations, including its retrospective design that has inherent bias toward selection criteria and the required follow-up components. For example, the duration of clopidogrel use prior to the index procedure was not recorded and/or available for the study. In addition, the use of and/or duration of other medications was not available and possible drug interactions were not evaluated. We were also limited by the comorbid conditions that were collected at the time of the index procedure. Finally, this study may have been slightly underpowered in that we did not reach full statistical significance for assisted primary patency and percutaneous interventions; therefore, these results have to be viewed with caution.</p>
</sec>
<sec id="section15-1538574413493678">
<title>Conclusions</title>
<p>This study suggests that aspirin is not inferior to dual antiplatelet therapy (clopidogrel and aspirin), loop AVGs may have a better primary-assisted patency, and percutaneous intervention may be superior to open surgical repair for patients with thrombosed AVGs. Further prospective randomized studies are needed before generalizing these results.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1538574413493678">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1538574413493678">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1538574413493678">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macdougall</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Eckardt</surname>
<given-names>KU</given-names>
</name>
<name>
<surname>Locatelli</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Latest US KDOQI Anaemia Guidelines update—what are the implications for Europe?</article-title> <source>Nephrol Dial Transplant</source>. <year>2007</year>;<volume>22</volume>(<issue>10</issue>):<fpage>2738</fpage>–<lpage>2742</lpage>.</citation>
</ref>
<ref id="bibr2-1538574413493678">
<label>2</label>
<citation citation-type="journal">
<collab collab-type="author">KDOQI</collab>. <article-title>KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target</article-title>. <source>Am J Kidney Dis</source>. <year>2007</year>;<volume>50</volume>(<issue>3</issue>):<fpage>471</fpage>–<lpage>530</lpage>.</citation>
</ref>
<ref id="bibr3-1538574413493678">
<label>3</label>
<citation citation-type="journal">
<collab collab-type="author">KDOQI</collab>. <article-title>KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease</article-title>. <source>Am J Kidney Dis</source>. <year>2007</year>;<volume>49</volume>(<issue>2 suppl 2</issue>):<fpage>S12</fpage>–<lpage>S154</lpage>.</citation>
</ref>
<ref id="bibr4-1538574413493678">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Doros</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Farber</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Comparison of the efficacy of upper arm transposed arteriovenous fistulae and upper arm prosthetic grafts</article-title>. <source>J Vasc Surg</source>. <year>2009</year>;<volume>50</volume>(<issue>6</issue>):<fpage>1405</fpage>–<lpage>1411</lpage>.<fpage>e1401</fpage>–<lpage>e1402</lpage>.</citation>
</ref>
<ref id="bibr5-1538574413493678">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dutka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brickel</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>A practical review of the kidney dialysis outcomes quality initiative (KDOQI) guidelines for hemodialysis catheters and their potential impact on patient care</article-title>. <source>Nephrol Nurs J</source>. <year>2010</year>;<volume>37</volume>(<issue>5</issue>):<fpage>531</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr6-1538574413493678">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>: <article-title>United States Renal Data System 2008 Annual Data Report</article-title>. <source>Am J Kidney Dis</source>. <year>2009</year>;<volume>53</volume>(<issue>suppl 1</issue>):<fpage>S1</fpage>–<lpage>S374</lpage>.</citation>
</ref>
<ref id="bibr7-1538574413493678">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vassalotti</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cohl</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Uribarri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Teodorescu</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Obese and non-obese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using pre-operative vein mapping</article-title>. <source>Clin Nephrol</source>. <year>2002</year>;<volume>58</volume>(<issue>3</issue>):<fpage>211</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr8-1538574413493678">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Herzog</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>US Renal Data System 2010 Annual Data Report</article-title>. <source>Am J Kidney Dis</source>. <year>2011</year>;<volume>57</volume>(<issue>1 suppl 1</issue>):<fpage>A8, e1</fpage>–<lpage>A8, e526</lpage>.</citation>
</ref>
<ref id="bibr9-1538574413493678">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sidawy</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Spergel</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Besarab</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access</article-title>. <source>J Vasc Surg</source>. <year>2008</year>;<volume>48</volume>(<issue>suppl 5</issue>):<fpage>2S</fpage>–<lpage>25S</lpage>.</citation>
</ref>
<ref id="bibr10-1538574413493678">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Adey</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>RD</given-names>
</name>
<etal/>
</person-group>. <article-title>KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients</article-title>. <source>Am J Kidney Dis</source>. <year>2010</year>;<volume>56</volume>(<issue>2</issue>):<fpage>189</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr11-1538574413493678">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallan</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>Orth</surname>
<given-names>SR.</given-names>
</name>
</person-group> <article-title>The KDOQI 2002 classification of chronic kidney disease: for whom the bell tolls</article-title>. <source>Nephrol Dial Transplant</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>2832</fpage>–<lpage>2836</lpage>.</citation>
</ref>
<ref id="bibr12-1538574413493678">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kramer</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) Grant Initiative: moving clinical practice forward</article-title>. <source>Am J Kidney Dis</source>. <year>2010</year>;<volume>55</volume>(<issue>3</issue>):<fpage>411</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr13-1538574413493678">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhlig</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berns</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kestenbaum</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).</article-title> <source>Am J Kidney Dis.</source> <year>2010</year>;<volume>55</volume>(<issue>5</issue>):<fpage>773</fpage>–<lpage>799</lpage>.</citation>
</ref>
<ref id="bibr14-1538574413493678">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of Dipyridamole plus aspirin on hemodialysis graft patency</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>21</issue>):<fpage>2191</fpage>–<lpage>2201</lpage>.</citation>
</ref>
<ref id="bibr15-1538574413493678">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufman</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>O'Connor</surname>
<given-names>TZ</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis</article-title>. <source>J Am Soc Nephrol</source>. <year>2003</year>;<volume>14</volume>(<issue>9</issue>):<fpage>2313</fpage>–<lpage>2321</lpage>.</citation>
</ref>
<ref id="bibr16-1538574413493678">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufman</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Use of aspirin in hemodialysis patients</article-title>. <source>Semin Dial</source>. <year>2001</year>;<volume>14</volume>(<issue>1</issue>):<fpage>72</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr17-1538574413493678">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>HI</given-names>
</name>
<name>
<surname>Kobrin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wasserstein</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hemodialysis vascular access morbidity</article-title>. <source>J Am Soc Nephrol</source>. <year>1996</year>;<volume>7</volume>(<issue>4</issue>):<fpage>523</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr18-1538574413493678">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trimarchi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Forrester</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Clopidogrel diminishes hemodialysis access graft thrombosis</article-title>. <source>J Vasc Access</source>. <year>2005</year>;<volume>6</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr19-1538574413493678">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duran</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Canbaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ege</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting</article-title>. <source>Platelets</source>. <year>2001</year>;<volume>12</volume>(<issue>8</issue>):<fpage>503</fpage>–<lpage>504</lpage>.</citation>
</ref>
<ref id="bibr20-1538574413493678">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davie</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>MP</given-names>
</name>
</person-group>. <article-title>CAPRIE trial</article-title>. <source>Lancet</source>. <year>1997</year>;<volume>349</volume>(<issue>9048</issue>):<fpage>355</fpage>.</citation>
</ref>
<ref id="bibr21-1538574413493678">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eriksson</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Creative cost-effectiveness analysis of CAPRIE data-dust in our eyes</article-title>. <source>Am J Med</source>. <year>2005</year>;<volume>118</volume>(<issue>2</issue>):<fpage>199</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr22-1538574413493678">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allon</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Stent graft or balloon angioplasty alone for dialysis-access grafts</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>(<issue>20</issue>):<fpage>1939</fpage>.</citation>
</ref>
<ref id="bibr23-1538574413493678">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crowther</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Clase</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Margetts</surname>
<given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial</article-title>. <source>J Am Soc Nephrol</source>. <year>2002</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2331</fpage>–<lpage>2337</lpage>.</citation>
</ref>
<ref id="bibr24-1538574413493678">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>McCloud</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Reikes</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Gellens</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial</article-title>. <source>J Am Soc Nephrol</source>. <year>2002</year>;<volume>13</volume>(<issue>1</issue>):<fpage>184</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr25-1538574413493678">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lok</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Allon</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Donnelly</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study</article-title>. <source>Clin Trials</source>. <year>2007</year>;<volume>4</volume>(<issue>4</issue>):<fpage>357</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr26-1538574413493678">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vergili-Nelsen</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Benefits of fish oil supplementation for hemodialysis patients</article-title>. <source>J Am Diet Assoc</source>. <year>2003</year>;<volume>103</volume>(<issue>9</issue>):<fpage>1174</fpage>–<lpage>1177</lpage>.</citation>
</ref>
<ref id="bibr27-1538574413493678">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dequiedt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Awada</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of fish oil rich in polyunsaturated fatty acids on hyperlipidemia of hemodialysis patients</article-title>. <source>Kidney Int Suppl</source>. <year>1989</year>;<volume>27</volume>:<fpage>S239</fpage>–<lpage>S242</lpage>.</citation>
</ref>
<ref id="bibr28-1538574413493678">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamazaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tateno</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients</article-title>. <source>Kidney Int</source>. <year>1984</year>;<volume>26</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr29-1538574413493678">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monroy-Cuadros</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yilmaz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Salazar-Bañuelos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Doig</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Risk factors associated with patency loss of hemodialysis vascular access within 6 months</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2010</year>;<volume>5</volume>(<issue>10</issue>):<fpage>1787</fpage>–<lpage>1792</lpage>.</citation>
</ref>
<ref id="bibr30-1538574413493678">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HC</given-names>
</name>
</person-group>. <article-title>Prevalence and risk factors for CKD in spouses and relatives of hemodialysis patients</article-title>. <source>Am J Kidney Dis</source>. <year>2010</year>;<volume>55</volume>(<issue>5</issue>):<fpage>856</fpage>–<lpage>866</lpage>.</citation>
</ref>
<ref id="bibr31-1538574413493678">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cull</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Carsten</surname>
<given-names>CG III</given-names>
</name>
<name>
<surname>Kalbaugh</surname>
<given-names>CA</given-names>
</name>
<etal/>
</person-group>. <article-title>The reverse J arteriovenous graft configuration for hemodialysis access: rationale, technique, and outcomes</article-title>. <source>Am Surg</source>. <year>2008</year>;<volume>74</volume>(<issue>7</issue>):<fpage>620</fpage>–<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr32-1538574413493678">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santoro</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Cambria</surname>
<given-names>RA.</given-names>
</name>
</person-group> <article-title>PTFE shunts for hemodialysis access: progressive choice of configuration</article-title>. <source>Semin Vasc Surg</source>. <year>1997</year>;<volume>10</volume>(<issue>3</issue>):<fpage>166</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr33-1538574413493678">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoffe</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Behar</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Scheinowitz</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A new mechanical device for declotting of hemodialysis access grafts: first clinical experience</article-title>. <source>J Endovasc Ther</source>. <year>2005</year>;<volume>12</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr34-1538574413493678">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turmel-Rodrigues</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Raynaud</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Louail</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Beyssen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sapoval</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Manual catheter-directed aspiration and other thrombectomy techniques for declotting native fistulas for hemodialysis</article-title>. <source>J Vasc Interv Radiol</source>. <year>2001</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1365</fpage>–<lpage>1371</lpage>.</citation>
</ref>
<ref id="bibr35-1538574413493678">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turmel-Rodrigues</surname>
<given-names>LA.</given-names>
</name>
</person-group> <article-title>Hemodialysis graft declotting with the “lyse and wait” technique: a new name for an old recipe</article-title>. <source>J Vasc Interv Radiol</source>. <year>1999</year>;<volume>10</volume>(<issue>1</issue>):<fpage>96</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr36-1538574413493678">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turmel-Rodrigues</surname>
<given-names>LA</given-names>
</name>
</person-group>. <article-title>Hemodialysis access declotting: a native fistula is not a prosthetic graft</article-title>. <source>J Vasc Interv Radiol</source>. <year>2000</year>;<volume>11</volume>(<issue>1</issue>):<fpage>135</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr37-1538574413493678">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enea</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Swank</surname>
<given-names>MD.</given-names>
</name>
</person-group> <article-title>Hemodialysis graft declotting: “lyse and wait” and watch</article-title>. <source>J Vasc Interv Radiol</source>. <year>1998</year>;<volume>9</volume>(<issue>4</issue>):<fpage>660</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr38-1538574413493678">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cynamon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lakritz</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>SI</given-names>
</name>
<etal/>
</person-group>. <article-title>Hemodialysis graft declotting: description of the “lyse and wait” technique</article-title>. <source>J Vasc Interv Radiol</source>. <year>1997</year>;<volume>8</volume>(<issue>5</issue>):<fpage>825</fpage>–<lpage>829</lpage>.</citation>
</ref>
<ref id="bibr39-1538574413493678">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dana</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Davy</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Druecke</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rethers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Angiography by the arterial route of arteriovenous fistula in hemodialysis patients [in French]</article-title>. <source>Ann Radiol (Paris)</source>. <year>1983</year>;<volume>26</volume>(<issue>5</issue>):<fpage>359</fpage>–<lpage>364</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>